A detailed history of Price T Rowe Associates Inc transactions in Altimmune, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 22,668 shares of ALT stock, worth $165,703. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,668
Previous 15,238 48.76%
Holding current value
$165,703
Previous $156,000 3.21%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.91 - $10.23 $43,911 - $76,008
7,430 Added 48.76%
22,668 $151,000
Q1 2024

May 15, 2024

BUY
$8.22 - $13.81 $14,968 - $25,148
1,821 Added 13.57%
15,238 $156,000
Q4 2023

Feb 14, 2024

BUY
$2.14 - $11.62 $7,211 - $39,159
3,370 Added 33.54%
13,417 $151,000
Q3 2023

Nov 14, 2023

SELL
$2.4 - $3.45 $37,440 - $53,820
-15,600 Reduced 60.83%
10,047 $27,000
Q2 2023

Aug 14, 2023

BUY
$3.45 - $5.97 $20,172 - $34,906
5,847 Added 29.53%
25,647 $91,000
Q1 2023

May 15, 2023

SELL
$4.19 - $16.83 $67,459 - $270,963
-16,100 Reduced 44.85%
19,800 $84,000
Q4 2022

Feb 14, 2023

SELL
$8.74 - $16.45 $862,760 - $1.62 Million
-98,714 Reduced 73.33%
35,900 $591,000
Q3 2022

Nov 14, 2022

BUY
$10.67 - $22.41 $1.06 Million - $2.22 Million
99,014 Added 278.13%
134,614 $1.72 Million
Q2 2022

Aug 15, 2022

SELL
$3.94 - $11.77 $13,604 - $40,641
-3,453 Reduced 8.84%
35,600 $417,000
Q1 2022

May 16, 2022

BUY
$5.9 - $9.45 $4,920 - $7,881
834 Added 2.18%
39,053 $238,000
Q4 2021

Feb 14, 2022

BUY
$8.69 - $12.48 $51,271 - $73,632
5,900 Added 18.26%
38,219 $350,000
Q3 2021

Nov 15, 2021

BUY
$8.43 - $16.81 $2,815 - $5,614
334 Added 1.04%
32,319 $366,000
Q2 2021

Aug 16, 2021

SELL
$9.85 - $16.46 $158,732 - $265,252
-16,115 Reduced 33.5%
31,985 $315,000
Q1 2021

May 17, 2021

BUY
$12.71 - $24.31 $90,241 - $172,601
7,100 Added 17.32%
48,100 $680,000
Q4 2020

Feb 16, 2021

BUY
$7.84 - $14.22 $321,440 - $583,020
41,000 New
41,000 $462,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $358M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.